FDA Request For Help On Hemp Regulation Gets Lower Profile In House Appropriators' Report

Committee’s report published with FY2025 appropriation states a different approach to establishing FDA regulation of non-drug products containing hemp as a derivative of cannabis de-scheduled as controlled substance in the US since 2018.

• Source: Shutterstock

House appropriators’ report published with their fiscal year 2025 appropriation bill for the US Food and Drug Administration could signal a shift in members’ thinking about the agency’s approach to effective regulation of the hemp products market.

[Sidebar#RS154892]

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Cannabis/CBD

More from Ingredients & Safety